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A Family with Isolated Hyperparathyroidism
Segregating a Missense MEN1 Mutation and Showing
Loss of the Wild-Type Alleles in the Parathyroid
Tumors
To the Editor:
Familial isolated primary hyperparathyroidism (FIHP, or
HRPT1; MIM 145000) is characterized by hypercal-
cemia, elevated parathyroid hormone (PTH) levels, and
uniglandular or multiglandular parathyroid tumors. The
diagnosis involves the exclusion of other familial dis-
orders characterized by primary hyperparathyroidism,
mainly multiple endocrine neoplasia type 1 (MEN1) and
hyperparathyroidism–jaw tumor syndrome (HPT-JT, or
HRPT2). To date, 170 FIHP families have been reported
(Huang et al. 1997), and FIHP has been proposed to be
either a distinct genetic entity or a variant of MEN1 or
of HPT-JT. MEN1 is characterized by tumors of the
parathyroids, the endocrine pancreas and duodenum,
and the anterior pituitary. Other associated features in-
clude adrenocortical tumors, lipomas, and carcinoids.
The MEN1 gene has been mapped to 11q13 (Larsson
et al. 1988) and was recently cloned (Chandrasekhar-
appa et al. 1997; The European Consortium on MEN1
1997). Frequent loss of heterozygosity (LOH) in MEN1-
related tumors (Friedman et al. 1994) and the inacti-
vating mutations found in patients and tumors (Agarwal
et al. 1997; Heppner et al. 1997) suggest that MEN1 is
a tumor-suppressor gene. HPT-JT is characterized by sol-
itary parathyroid adenomas/carcinomas and fibro-os-
seous jaw tumors and occasionally by renal lesions,
namely, Wilm tumors, polycystic kidney disease, and re-
nal hamartomas (Szabo et al. 1995; Teh et al. 1996a).
The HRPT2 gene, which has been mapped to 1q21-q32
but which has not yet been cloned, is also considered to
be a tumor-suppressor gene (Teh et al. 1996a).
We recently have found that, in two FIHP families
characterized by solitary adenomas, the disease was
linked to 1q21-q32, suggesting that a subset of FIHP
forms a variant of HPT-JT (Teh et al. 1998b). On the
other hand, linkage to MEN1 has also been implicated
in one FIHP family, but without conclusive evidence
(Kassem et al. 1994). The recent cloning of the MEN1
gene has allowed mutation analysis of FIHP kindreds,
but, to date, no MEN1 mutation has been found in the
nine small families analyzed (Agarwal et al. 1997; Teh
et al. 1998a). We report a large family in which seven
members are affected with primary hyperparathyroidism
without association of other tumors, and we present
genetic data to demonstrate that this is a MEN1 variant.
The family is of Caucasian origin and resides in Eng-
land. Seven family members from two generations were
found to have primary hyperparathyroidism (fig. 1 and
table 1). The present age and age at diagnosis of para-
thyroid disease is detailed for each family member in
table 1. Five family members have had parathyroid
glands surgically removed, whereas two declined sur-
gery. The index case (II-3) had three enlarged parathy-
roid glands removed at the first operation, and, subse-
quently, a mediastinal parathyroid tumor was removed,
because of persistent disease. Subject II-2 had four
enlarged glands removed, and subjects III-4, III-5, and
III-8 each had three or three and a half enlarged glands
removed. Histopathologically, the parathyroid glands
were classified as hyperplastic and did not demonstrate
any evidence of cysts or malignancy. Patients II-4 and
III-9 declined surgery and were diagnosed as affected,
on the basis of borderline hypercalcemia (2.6 mmol/liter
each; reference range 2.20–2.60 mmol/liter) in combi-
nation with repeated increased PTH levels (113 pg/ml
and 99 pg/ml, respectively; normal range 10–50 pg/ml).
Subject I-1, who died from myocardial infarction at the
age of 77 years, was known to have renal calculi, sug-
gesting that he was also affected. None of the patients
have clinical or biochemical evidence of MEN1 or
MEN2. The family has been followed, at the Department
of Medicine at King’s College, with annual hormonal
profiles, determined since 1994. Fasting serum gut-hor-
mone profiles (insulin, pancreatic polypeptide, vasoac-
tive intestinal polypeptide, gastrin, glucagon, somato-
statin, and neurotensin) are all within normal ranges.
Pentagastrin-stimulated serum calcitonin levels are all
undetectable. Twenty-four–hour urinary catecholamine
metabolites are within the normal ranges. Computed
tomography and magnetic-resonance imaging of the ab-
domen did not detect any tumor of the pancreas and
adrenal glands. No patients have evidence of a pituitary
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Figure 1 a, Pedigree showing the family with autosomal dominantly inherited isolated hyperparathyroidism. Blackened symbols indicate
affected family members, and unblackened symbols indicate unaffected family members. The gray-shaded symbol indicates that the individual
(I-1) probably is affected, and the symbols with a question mark (?), in generation IV, indicate that the individuals are still at risk. The results
from mutation analysis using restriction cleavage are shown below the pedigree. b, Illustration showing the HindIII site created by the E255K
mutation.
tumor, either on skull radiography or on magnetic-res-
onance imaging, and their pituitary hormonal profiles,
including prolactin, growth hormone, and adrenocor-
ticotropic hormone, are within the normal range. In ad-
dition, no family member has any clinical evidence of
HPT-JT. Orthopentography of the jaw was carried out
on all affected family members, but no case of jaw tumor
was found.
Consent was obtained from the participating family
members, and the study was approved by the local ethics
committee. Genomic DNA was extracted from periph-
eral leukocytes of 17 individuals and from fresh frozen
tumor tissues as well as tissue blocks from the parathy-
roid operations of four affected individuals (table 2).
Constitutional DNA was genotyped for the polymorphic
microsatellite markers D11S956, PYGM, D11S787, and
INT2, within the MEN1 region at 11q13 (The European
Consortium on MEN1 1996), and D1S218, D1S222,
D1S428, D1S412, D1S413, and D1S510, from the
HRPT2 region in 1q21-q32 (Teh et al. 1996a). Paired
constitutional and tumor DNA samples were analyzed
for LOH by use of D11S956, PYGM, INT2, D11S787,
D11S419, HBB, D11S1378, and TYR.
Linkage to the HRPT2 locus in 1q21-q32 was ex-
cluded by significantly negative LOD scores (!2) and
by haplotyping (data not shown). We thus focused on
the other candidate region, that is, the MEN1 locus in
chromosome 11q13. The seven affected members all
shared the disease-associated haplotype constructed for
four markers flanking the MEN1 gene (not shown).
LOH was identified with the same markers, in 5 of 11
tumors analyzed (table 2 and fig. 2). For all informative
cases, these 5 tumors also showed LOH for the six ad-
ditional chromosome 11 loci tested, suggesting loss of
one entire chromosome 11 homologue (fig. 2). Com-
bined analyses of the constitutional and tumor genotypes
revealed that the losses invariably involved the wild-type
alleles derived from the unaffected parent. Two-point
linkage calculations were then performed by incorpo-
ration of the results from constitutional genotyping and
LOH analysis, by use of a modification of the LINKAGE
program (Cottingham et al. 1993; Rohde et al. 1995).
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Table 2
Results from LOH Studies of the Parathyroid Tumors, Using
Microsatellite Markers within the MEN1 Region at 11q13
Patient
and Gland
Number D11S956 PYGM D11S787 INT2 Allele Lost
II-2:
1    
II-3:
1 LOH LOH LOH LOH Wild-type
2 LOH  LOH  Wild-type
3    
4   LOH  Wild-type
III-4:
1 LOH LOH  LOH Wild-type
2    
3 LOH LOH  LOH Wild-type
III-5:
1    
2    
3    
NOTE.—A plus sign () indicates retained heterozygosity, and a
minus sign () indicates not informative or not done.
Table 1

















I-1 Male Deceased NA NA NA NA NA Renal calculi
II-2 Male 70 66 2.86 Yes Yes 4 Renal calculi
II-3 Male 52 46 3.20 Yes Yes 4 Renal calculi and
hypertension
II-4 Female 71 69 2.60b Yes Yes Declined surgery )
III-4 Male 40 38 2.84 Yes Yes 132 )
III-5 Female 39 38 3.00 Yes Yes 132 )
III-8 Female 51 37 NA Yes Yes 3 Renal calculi and
hypertension
III-9 Female 47 45 2.60b Yes Yes Declined surgery )
IV-1 Male 16 ) 2.39 Yes Yes ) )
IV-2 Female 14 ) 2.39 Yes Yes ) )
IV-3 Male 12 ) 2.45 No No ) )
IV-4 Male 10 ) 2.45 No No ) )
IV-5 Male 28 ) 2.39 Yes Yes ) )
IV-6 Male 15 ) NA Yes Yes ) )
IV-7 Female 19 ) 2.39 No No ) )
NOTE.—NA  not available or not applicable.
a Corrected to serum albumin of 40 g/liter (normal range 2.20–2.60 mmol/liter). PTH levels are not given, since these were
measured by use of different assays at different centers.
b Patient had borderline hypercalcemia and increased PTH levels (113 pg/ml in II-4 and 99 pg/ml in III-9; normal range 10–50
pg/ml).
For D11S956 and PYGM, the maximum LOD scores of
2.48 and 1.99, respectively, were obtained at a recom-
bination fraction of .00. Taken together, the results in-
dicate the involvement of a tumor-suppressor gene in
11q13, presumably the MEN1 gene, in this family.
The MEN1 gene was screened for mutations by use
of single-strand conformation analysis (SSCA) and se-
quencing, as described elsewhere (The European Con-
sortium on MEN1 1997). By SSCA an aberrant shift
was detected in the exon 4 fragment (192 bp). This shift
was present in all seven affected cases and in four at-
risk individuals in generation IV (aged 14, 15, 16, and
28 years; table 1). However, the shift was not detected
in unrelated spouses in the family or in 150 unrelated
individuals. Direct sequencing revealed a missense mu-
tation in codon 255 (GAGrAAG) of exon 4, causing
an amino acid change from glutamic acid to lysine
(E255K or c.763GrA). This GrA transition also gave
rise to a HindIII restriction-cleavage site (AAGCTT) for
the mutant allele. As the result of the enzyme cleavage,
two bands of 144 bp and 44 bp were obtained that were
consistent with the SSCA results (fig. 1). The results from
the mutation analysis were completely in agreement with
those obtained by haplotyping of the 11q13 markers
(table 1).
It is now established that mutations in some familial
cancer genes can give rise to similar but distinct clinical
variants. For example, specific mutations of the RET
proto-oncogene are associated with each of the three
variants of multiple endocrine neoplasia type 2 (MEN2),
that is, MEN2A, MEN2B, and familial medullary car-
cinoma of the thyroid (Eng 1996). For MEN1, many
researchers have tried to determine clinically distinct var-
iants. Reports of FIHP and familial pituitary tumors, for
example, are abundant, but, to date, there is no conclu-
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Figure 2 Autoradiograms showing LOH in the whole of chromosome 11 in parathyroid tumor 1 from patient II-3 (D11S419, D11S787,
and D11S1378) and in two of the three tumors from patient III-4 (HBB, D11S956, PYGM, INT2, and TYR). Lane B, Leukocyte DNA. Lane
T, Tumor DNA.
sive genetic evidence to confirm that they are a variant
of MEN1 (Teh et al. 1998c).
To our knowledge, this is the first study to demon-
strate that FIHP can occur as a variant of MEN1, and
in this family FIHP is associated with a MEN1 missense
mutation. The disease transmission follows an auto-
somal dominant pattern with high penetrance, as in
MEN1. Clinically, the hyperparathyroidism runs a
rather mild course, as evidenced by two affected subjects
who declined surgery and yet developed no obvious
complications. Pathologically, the multiglandular para-
thyroid disease found is also consistent with that of
MEN1 (Teh et al. 1996b). Furthermore, LOH results of
the parathyroid tumors indicated the involvement of the
MEN1 gene, which has been considered to be a tumor-
suppressor gene. The loss of the wild-type alleles in the
parathyroid tumors from two individuals is consistent
with Knudson’s two-hit mutation theory. Thus, in these
tumors, one copy of the MEN1 gene is mutated with
E255K, whereas the other copy is lost. We thus propose
that FIHP could be divided into at least two forms, on
the basis of histopathological and genetic findings. The
MEN1 variant is characterized by multiglandular hy-
perplastic disease resulting from a MEN1 mutation and,
clinically, by a milder course of hyperparathyroidism.
The HPT-JT variant characterized by solitary adenomas
is linked to the HRPT2 locus in 1q21-q32 and more
frequently presents with profound hypercalcemia or hy-
percalcemic crisis.
To date, the function of the MEN1 gene remains un-
known. A wide range of MEN1 mutations, spreading
across all nine coding exons, have been reported, al-
though a large proportion of them are frameshift or
nonsense, indicating that they are inactivating muta-
tions. The missense mutation found in this family
(E255K) has never been reported either in MEN1 fam-
ilies (Basset et al. 1998; Teh et al. 1998c; Genome Da-
tabase) or in sporadic counterparts of MEN1-related
tumors, including parathyroid tumors (Heppner et al.
1997; Farnebo et al. 1998). By comparison with the
murine Men1 sequence, this mutation was shown to af-
fect a conserved amino acid (C.L., unpublished data).
Although the significance of this mutation, which alters
glutamic acid to lysine in codon 255, is not known, our
findings suggest that it contributes relatively mildly to
parathyroid hyperplasia and not to other MEN1-related
neoplasias. However, the family members carrying the
mutation should be considered as potential MEN1 pa-
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tients and should have close long-term follow-up. Future
functional studies of the mutation in the family reported
here, compared with others, will provide information
relevant to elucidating the biological roles of the MEN1
gene, in various endocrine tissues.
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